Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02234986 · ClinicalTrials.gov registry record · Phase 2
A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
A Phase 2 study, sponsored by CASI pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT02234986 is a Phase 2 study that has completed, run by CASI pharmaceuticals. The registered enrollment target is 35 participants.
The verdict
NCT02234986, a Phase 2 study, has completed, sponsored by CASI pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether once-daily dosing with ENMD-2076 will be a safe and effective treatment in patients with FLC. Safety will be measured by looking at the adverse events that may happen and the efficacy will look at the progression of the disease over time.
Interventions
- DRUG ENMD-2076
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2015-10 |
| Est. Completion | 2018-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02234986
The ClinicalTrials.gov registry entry for NCT02234986 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CASI pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ENMD-2076 is the first listed.
NCT02234986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02234986 about?
NCT02234986 is a clinical study titled "A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma". The purpose of the study is to determine whether once-daily dosing with ENMD-2076 will be a safe and effective treatment in patients with FLC. Safety will be measured by looking at the adverse events that may happen and the efficacy will look at the progression of the disease over time.
What is the current status of trial NCT02234986?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2015-10. Estimated completion is 2018-06-30.
What interventions are being tested in trial NCT02234986?
The interventions under investigation include: ENMD-2076 (DRUG).
Who is sponsoring clinical trial NCT02234986?
This trial is sponsored by CASI pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.